Akari Therapeutics (AKTX) Goodwill & Intangibles (2014 - 2026)
Akari Therapeutics (AKTX) reported Goodwill & Intangibles of $38.7 million for Q1 2026, down 18.65% on a YoY basis from $47.6 million in Q1 2025, and down 8.72% sequentially from $42.4 million in Q4 2025.
Akari Therapeutics (AKTX) Goodwill & Intangibles (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 13 years of Goodwill & Intangibles data on file, last reported at $38.7 million in Q1 2026.
- For the quarter ending Q1 2026, Goodwill & Intangibles fell 18.65% year-over-year to $38.7 million; the trailing twelve-month figure through Mar 2026 stood at $38.7 million (down 18.65% YoY), and the FY2025 full-year result was $42.4 million, down 10.88% from the prior year.
- Goodwill & Intangibles declined to $38.7 million in Q1 2026, from $42.4 million in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $47.6 million in Q4 2024 to a low of $14000.0 in Q4 2023.
- A 5-year average of $32.3 million and a median of $40.6 million in 2025 frame the typical range for Goodwill & Intangibles.
- Across the five-year window, Goodwill & Intangibles retreated 25.86% in 2022 and jumped 339971.43% in 2024, its largest moves.
- Tracing AKTX's Goodwill & Intangibles over 5 years: stood at $17000.0 in 2022, then dropped by 17.65% to $14000.0 in 2023, then jumped by 339971.43% to $47.6 million in 2024, then dropped by 10.88% to $42.4 million in 2025, then fell by 8.72% to $38.7 million in 2026.
- Business Quant data shows AKTX's Goodwill & Intangibles at $38.7 million in Q1 2026, $42.4 million in Q4 2025, and $34.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.73 Mn |
| Dec 31, 2025 | 42.43 Mn |
| Sep 30, 2025 | 34.00 Mn |
| Jun 30, 2025 | 47.61 Mn |
| Mar 31, 2025 | 47.61 Mn |
| Dec 31, 2024 | 47.61 Mn |
| Dec 31, 2023 | 14,000.00 |
| Dec 31, 2022 | 17,000.00 |
| Dec 31, 2021 | 22,929.00 |
| Dec 31, 2020 | 27,150.00 |
| Sep 30, 2020 | 26,674.00 |
| Jun 30, 2020 | 26,489.00 |
| Mar 31, 2020 | 27,566.00 |
| Dec 31, 2019 | 30,163.00 |
| Sep 30, 2019 | 29,147.00 |
| Jun 30, 2019 | 31,065.00 |
| Mar 31, 2019 | 32,867.00 |
| Dec 31, 2018 | 32,978.00 |
| Dec 31, 2017 | 39,124.00 |
| Dec 31, 2016 | 39,365.00 |